Group Financial Results as of March 31st 2024 Approved, Continued Growth and EBITDA Margin Expansion, Euro 500 Million Share Buy-Back Program Launched

Group Financial Results as of March 31st 2024 Approved, Continued Growth and EBITDA Margin Expansion, Euro 500 Million Share Buy-Back Program Launched

  • Revenues at € 781.6 million   in 1Q24, +6.0% Y/Y
  • EBITDA at € 361.7 million in 1Q24, +8.6% Y/Y, with c. +112 bps EBITDA margin expansion
  • 2024 Guidance confirmed
  • Up to € 500 million share buy-back program launched today

The Board of Directors of Nexi S.p.A. approved on May 8 th the Group's consolidated financial results as of March 31 st 2024.

Key consolidated financial managerial results 1

In 1Q24 the Group delivered revenues at € 781.6 million, +6.0% versus 1Q23, and EBITDA at € 361.7 million, +8.6% versus 1Q23. The EBITDA margin was at 46%, up by 112 basis points compared to 1Q23, also thanks to the accelerating efficiencies and cost synergies delivery on the back of Group integration.

Nexi Group's operating businesses delivered the following results in 1Q24:

  • Merchant Solutions, representing approximately 56% of Group's total revenues, reported revenues of € 437.7 million, +6.8% Y/Y, with eCommerce growing double-digit driven by accelerated customer base growth and volume growth. In 1Q24, 4,514 million transactions were processed, +9.5% Y/Y, with value of processed transactions at € 192.5 billion, +5.0% Y/Y. In 1Q24 there has been a continued international schemes sales volume growth in all geographies, with DACH region growing double-digit Y/Y and Italy high single-digit. During the quarter, SMEs acquiring volumes continued to grow driven by customer base expansion, particularly in Italy and DACH region.

    Nexi firmly believes that convergence of digital payments and software for SME is a topic that will contribute to shape the industry in the next years. Therefore, Nexi continues to reinforce its position as the "partner of choice" in Europe for best-in-class local ISVs, with >500 ISVs partners in 8 markets and POS solutions already being sold by Nexi channels in the Nordics and Germany, to be extended over time to additional markets and verticals.
  • Issuing Solutions, representing approximately 33% of Group's total revenues, reported revenues of € 257.6 million in 1Q24, +5.2% Y/Y. The growth was mainly supported by the performance in Italy, benefitting from the acceleration of international debit. In 1Q24, 4,737 million transactions were processed, +8.2% Y/Y, with value of processed transactions at € 207.9 billion, +4.6% Y/Y.
  • Digital Banking Solutions, representing approximately 11% of Group's total revenues, reported revenues of € 86.3 million, +4.3% Y/Y, sustained by volume growth and positive impact from new initiatives. Specifically, during the first quarter, Nexi launched a new pan-European antifraud solution for EBA Clearing's SEPA credit transfers and Instant payments.

In 1Q24, Total Costs were at € 419.9 million, with a growth of 3.8% Y/Y mainly thanks to the operating leverage and to synergies and efficiencies, as well as some phasing effects, despite volume and business growth and inflationary pressure.

As of March 31 st 2024, the Net Financial Debt was down to € 5,035 million, while the Net Financial Debt / EBITDA ratio decreased at 2.8x. The weighted average debt maturity is ~2.8 years with an average pre-tax cash cost of debt, stable versus FY23, of ~2.86%. With reference to the ~€ 1.3 billion of 2024-2025 debt maturities, Nexi confirms its plan to fully pay down them with the existing cash; in particular, ~€ 220 million have been already reimbursed in April 2024.

2024 Guidance confirmed

For 2024, considering the persistent complex macro-outlook, Nexi confirms the following targets:

  • Net revenues: Mid-single digit Y/Y growth;
  • EBITDA: Mid-to-high single digit Y/Y growth, with margin expansion of 100 bps+;
  • Excess cash generation: More than € 700 million;
  • Net leverage: decreasing to below 2.9x including announced M&A and share buy-back effects, (~2.6x on organic basis).

Significant subsequent events

  • Nexi announces the start of a share buy-back program up to 500 €M to be completed by October 31 st , 2025 and already approved by the Shareholders' meeting on April 30 th , 2024.

    The substantial existing cash balances and the strong current and expected cash generation growth allow to start returning capital to Shareholders in 2024, while still continuing to support the planned debt reduction and the limited M&A opportunities in the future. Nexi's management and the Board believe that the current share price does not reflect the full value of its business and outlook and that a share buy-back offers the most effective value creating opportunity for the shareholders to deploy the excess cash. In the longer term, Nexi plans to continue to allocate a material portion of excess capital to shareholders either through further share buy-back programs or dividends depending on overall market conditions.
  • On April 8 th , 2024, the bonds issued by Nassa TopCo AS for a nominal amount of about € 219.6 million, plus the accrued interest, were redeemed at maturity using the already available cash.
  • Following the resignation of Mr. Bo Nilsson from the Board of Directors occurred on April 30 th , 2024, the Board of Directors of the Company during yesterday's meeting, appointed by co-optation Mr. Luca Velussi as a non-executive and non independent Director, after the favorable opinion of the Board of Statutory Auditors. His curriculum vitae is available in the governance section of the company website www.nexigroup.com . Mr. Luca Velussi will remain in post until the next Shareholders' Meeting and, as of today, does not own any Nexi share.

Pursuant to paragraph 2 of article 154 bis of the Consolidated Finance Act, the undersigned, Enrico Marchini, in his capacity as the manager in charge of preparing Nexi's financial reports, declares that the accounting information contained in this press release corresponds to the accounting documents, books and records of Nexi S.p.A..

Disclaimer: This is the English translation of the original Italian press release "Approvati i risultati finanziari di Gruppo al 31 marzo 2024". In any case of discrepancy between the English and the Italian versions, the original Italian document is to be given priority of interpretation for legal purposes.

Nexi

Nexi is Europe's PayTech company operating in high-growth, attractive European markets and technologically advanced countries. Listed on Euronext Milan, Nexi has the scale, geographic reach and abilities to drive the transition to a cashless Europe. With its portfolio of innovative products, e-commerce expertise and industry-specific solutions, Nexi provides flexible support for the digital economy and the entire payment ecosystem globally, across a broad range of different payment channels and methods. Nexi's technological platform and the best-in-class professional skills in the sector enable the company to operate at its best in three market segments: Merchant Solutions, Issuing Solutions and Digital Banking Solutions. Nexi constantly invests in technology and innovation, focusing on two fundamental principles: meeting, together with its partner banks, customer needs and creating new business opportunities for them. Nexi is committed to supporting people and businesses of all sizes, transforming the way people pay and businesses accept payments. It offers companies the most innovative and reliable solutions to better serve their customers and expand. By simplifying payments and enabling people and businesses to build closer relationships and grow together, Nexi promotes progress to benefit everyone. www.nexi.it/en www.nexigroup.com

1 2023 and 2024 pro-forma normalised managerial data at constant scope and FX (average 2024 budget FX).

Nexi - External Communication & Media Relations

D   aniele de Sanctis  
daniele.desanctis@nexigroup.com
Mobile: +39 346 0151000

Matteo Abbondanza  
matteo.abbondanza@nexigroup.com
Mobile: +39 348 4068858

Søren Winge  
soeren.winge@nexigroup.com
Mobile: +45 29482635

Danja Giacomin  
danja.giacomin@nexigroup.com
Mobile: +39 334 2256777

Nexi - Investor Relations  
Stefania Mantegazza  
stefania.mantegazza@nexigroup.com
Mobile: +39 335 5805703

News Provided by Business Wire via QuoteMedia

NEXI
The Conversation (0)

Bloomberg Asharq will Deploy Avid Tools and Solutions

Avid (NASDAQ:AVID) announced that Bloomberg Asharq has picked Avid’s tools and solutions to establish TV news production infrastructure.

As quoted in the text release:

Keep reading...Show less

Avid and FotoKem Renew Multi-year Enterprise Agreement

Avid (NASDAQ:AVID) on Monday announced that it has renewed its multi-year enterprise agreement with FotoKem.

As quoted in the press release:

Keep reading...Show less

Avid Signs Multi-year Enterprise Agreement with Carolina Panthers

Avid (NASDAQ:AVID) announced that Carolina Panthers has entered into a six year enterprise agreement with Avid to  standardize its media production as it seeks to drive engagement and enhance fan experience.

As quoted in the press release:

Keep reading...Show less

Full Sail University Collaborates with Avid to Deliver Unique Learning Experience for Students

Avid (NASDAQ:AVID) announced that Full Sail University has become an Avid Media Campus site with Full Sail implementing latest tools from Avid to deliver unique learning experience for students.

Further, the company said that the Avid Learning Partner Program will provide the required coursework for students to become Avid certified.

Keep reading...Show less

TV 2 DENMARK Expands Relationship with Avid for Next-generation News Production

Avid (NASDAQ:AVID) announced a multi-year strategic relationship with TV 2, the premier broadcaster in Denmark  for next generation news production with the company equipping the newsroom with latest tools and solutions from Avid.

The company said that its MediaCentral platform will serve as a foundation for TV2’s news production and that it will enhance collaboration, increase efficiency and productivity.

Keep reading...Show less
Sona Nanotech

Sona Nanotech Grants Options

Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona") is pleased to announce that it has granted 25,000 incentive stock options under the Company's Stock Option Plan ("Option Plan") to a consultant. Each option is exercisable into one common share at a price of $0.30 per share and will vest at the rate of 25% every six months. The options will expire five years from the date of grant. All other terms and conditions of the options are in accordance with the terms of the Company's Option Plan.

Contact:
David Regan, CEO
+1-902-536-1932
david@sonanano.com

Keep reading...Show less
Sona Nanotech

Sona Nanotech


Keep reading...Show less
Longeveron to Present at the Emerging Growth Virtual Conference on June 12, 2024

Longeveron to Present at the Emerging Growth Virtual Conference on June 12, 2024

Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing regenerative medicines, today announced that it will participate in the Emerging Growth Virtual Conference taking place June 12-13, 2024.

Details for the Company's presentation:

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Veru to Present at the American Diabetes Association's 84th Scientific Sessions

Veru to Present at the American Diabetes Association's 84th Scientific Sessions

Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced that the Company will present two presentations at the American Diabetes Association's 84 th Scientific Sessions, taking place June 21-24, 2024, in Orlando, Florida.

The presentations are:

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Dr. Giovanni Selvaggi, Who Has Brought Several Oncology Drugs to Market, Joins CEL-SCI as Clinical Advisor

Dr. Giovanni Selvaggi, Who Has Brought Several Oncology Drugs to Market, Joins CEL-SCI as Clinical Advisor

  • Dr. Selvaggi was instrumental in the development and approval of lung cancer drugs Zykadia for Novartis and Opdivo for Bristol Myers Squibb
  • CEL-SCI's Multikine immunotherapy improves the 5-year survival of head and neck cancer patients to 73% compared to 45% in controls and cuts the 5-year risk of death by 50%
  • FDA has given CEL-SCI the go-ahead to commence a confirmatory Registration Study for Multikine for the target population in head and neck cancer
  • Dr. Selvaggi will be supporting CEL-SCI to bring Multikine to patients through a confirmatory registrational path that has been agreed with regulatory authorities and that has a potential for cure

CEL-SCI Corporation (NYSE American: CVM) today announced Dr. Giovanni Selvaggi, an oncology key opinion leader instrumental in successfully bringing several drugs to market has joined CEL-SCI as a Clinical Advisor. Dr. Selvaggi joins CEL-SCI as the Company recently received its go-ahead from the U.S. Food and Drug Administration (FDA) for its confirmatory Registration Study of Multikine* in the treatment of head and neck cancer.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240606671425/en/

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Ventyx Biosciences Announces Positive Preclinical Data for CNS-Penetrant NLRP3 Inhibitor VTX3232 Demonstrating Reversal of Obesity and Improvements in Cardiometabolic and Inflammatory Markers

VTX3232 demonstrated improvements in body weight, systemic inflammatory biomarkers and cardiometabolic parameters in diet-induced obesity (DIO) mice

Additive effects were observed for VTX3232 in combination with the GLP-1 receptor agonist semaglutide across key endpoints compared to semaglutide or VTX3232 alone

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×